FDA warns of shortage of Eli Lilly's diabetes drugs
Eli Lilly is now falling short of meeting the full demand for its newest type 2 diabetes drug, Mounjaro (tirzepatide) – and the US Food and Drug Administration (FDA) has added the product to its list of potential shortages, reports news media Reuters.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Eli Lilly to double Mounjaro production
For subscribers
Eli Lilly expects 2023 revenue to pass USD 30bn mark
For subscribers